In our referral Institute, we treated women with ovarian cancers coming from all the Italian regions and from other European or North-African countries and our prevalence of P/LP alterations were consistent with previous studies reporting a frequency of P/LP alterations from 19% to 32% in ovarian cancers, mainly of the BRCA1 (75–61%) gene [20,23,36,37]. This evidence concerns the gene BRCA1 and ovarian cancer.